Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.

XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its smart steerable guidewires and robotic systems, successfully completed a first-of-its-kind live telerobotic trial for stroke treatment between Abu Dhabi and South Korea at Abu Dhabi Global Healthcare Week.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments.

This announcement summarizes Bioretec Ltd's business review for January-March 2024.

INVO Bioscience, Inc. announced financial results for the first quarter of 2024 and provided a business update.

Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the first quarter ended March 31, 2024.